Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
Companies To Watch
XXII 1.45 N/A CKPT 9.00 N/A CPHR 2.99 N/A CFRX 1.25 N/A CRBP 5.80 N/A DMPI 2.12 N/A DVAX 9.25 N/A FBIO 4.48 N/A KERX 7.06 N/A MTNB 1.24 N/A MDGN 5.57 N/A MNOV 5.22 N/A MTFB 7.59 N/A PRQR 5.15 N/A STML 9.75 N/A SYN 0.501 N/A TGTX 11.55 N/A THLD 0.50 N/A TNXP 3.90 N/A URGN 18.40 N/A VSTM 3.60 N/A ZIOP 5.65 N/A 2017-07-27 15:59